Comparison 2. Repaglinide versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.1 Change in FEV1 (% predicted)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.1.1 At 12 months	1	38	Mean Difference (IV, Fixed, 95% CI)	1.70 [‐5.13, 8.53]
2.2 Change in FVC (% predicted)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.2.1 At 12 months	1	38	Mean Difference (IV, Fixed, 95% CI)	‐1.00 [‐7.40, 5.40]
2.3 Change in BMI	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.3.1 At 12 months	1	38	Mean Difference (IV, Fixed, 95% CI)	0.17 [‐0.47, 0.81]
2.4 Hypoglycemia	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.4.1 At 2 months	1	14	Risk Ratio (M‐H, Fixed, 95% CI)	1.00 [0.08, 13.02]
2.4.2 At 3 months	1	51	Risk Ratio (M‐H, Fixed, 95% CI)	12.52 [0.74, 211.20]